Lucosky Brookman is pleased to announce its representation of Kingswood Investments, a division of Kingswood Capital Partners LLC, in Telomir Pharmaceuticals, Inc.’s (Nasdaq: TELO) recent initial public offering (IPO). Telomir Pharmaceuticals, a pre-clinical-stage pharmaceutical company pioneering the development and commercialization of Telomir-1, closed its IPO on February 9, 2024, marking a significant milestone for the company and its innovative approach to age reversal.
